
==== Front
NPJ Parkinsons Dis
NPJ Parkinsons Dis
NPJ Parkinson's Disease
2373-8057
Nature Publishing Group UK London

39256426
787
10.1038/s41531-024-00787-y
Article
Orthostatic Hypotension: a clinical marker for the body-first subtype of patients with Parkinson’s Disease
Mei Shanshan 12
Wang Xue 1
Mao Wei 12
Liu Yue 3
Tian Zichen 4
Han Chao pumc_hanchao@163.com

5
http://orcid.org/0000-0002-4620-1268
Chan Piu pbchan@hotmail.com

1256
1 https://ror.org/013xs5b60 grid.24696.3f 0000 0004 0369 153X Department of Neurology, Xuanwu Hospital Capital Medical University, Beijing, China
2 Key Laboratory on Neurodegenerative Disorders of Ministry of Education, Key Laboratory on Parkinson’s Disease of Beijing, Beijing, China
3 Department of Neurology, Boren Hospital, Beijing, China
4 https://ror.org/03x3g5467 Washington University School of Medicine, St. Louis, MI USA
5 https://ror.org/013xs5b60 grid.24696.3f 0000 0004 0369 153X National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital Capital Medical University, Beijing, China
6 https://ror.org/013xs5b60 grid.24696.3f 0000 0004 0369 153X Parkinson’s Disease Center of Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Xuanwu Hospital Capital Medical University, Beijing, China
11 9 2024
11 9 2024
2024
10 1739 2 2024
20 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Our study aimed to investigate the clinical characteristics of PD patients stratified by OH status before and after levodopa challenge to explore the hypothesis that OH might serve as a clinical marker for the body-first subtype of PD. Supine and standing blood pressure were measured in a large cross-sectional cohort of PD patients at the OFF status before and after levodopa challenge test (LCT). Based on OH status, patients were divided into three groups: spontaneous OH (SOH), only levodopa-induced OH (LOH) and non-OH (NOH). Clinical characteristics and associated factors were compared among the groups. A total of 928 patients with a mean age of 62.4 years and average disease duration of 7.9 years were included. There were 224 (24.1%) patients with SOH, 321 (34.6%) with LOH, and 383 (41.3%) with NOH. Compared to NOH, both SOH and LOH were associated with older age, motor fluctuations, and probable rapid eye movement sleep behavior disorder (pRBD). In addition, OH was more associated with cardiovascular and digestive dysfunction, disease severity and worse quality of life. Results of the current study suggest that PD patients developed OH which is more likely to comorbid with RBD, severe autonomic dysfunction and motor fluctuations, consistent with the body-first subtype of PD.

Subject terms

Parkinson's disease
Prognostic markers
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) No. 82201401 Han Chao Xuanwu Youth Development Project (No. QNPY2021011).National Key R&D Program of China (No. 2021YFC2501200, No.2018YFC1312001)issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Parkinson’s disease (PD) is characterized mainly by loss of dopaminergic neurons residing in the substantia nigra and thought to be a primary brain disorder. Recently, it has be recognized that PD is highly heterogeneous and probably consists of several subtypes due to the nature of wide spreading of α-synuclein (α-syn) aggregations and non-motor symptoms1,2. Borghammer et al. hypothesized that PD comprises two subtypes including body-first subtype in which pathological α-syn originates from the peripheral nervous system (PNS) and brain-first subtype in which α-syn initiates in the central nervous system (CNS)3,4. PD patients with body-first and brain-first subtypes have various clinical characteristics4. However, there is currently no definite marker available that can clearly differentiate between body-first and brain-first subtype of PD.

Most of previous literatures distinguished these two subtypes of PD based on rapid eye movement sleep behavior disorder (RBD)-status5,6. However, according to α-syn origin and connectome model (SOC model) proposed4, α-syn pathology propagates from enteric to cardiovascular autonomic system, then to brain. Therefore, digestive, and cardiovascular autonomic dysfunctions are also the major characteristics of PD patients with body-first subtype. Orthostatic hypotension (OH), as the hallmark feature of cardiovascular and autonomic dysfunction, had been reported to be highly related to RBD7–9. The combination of OH and RBD reflects a ‘malignant’ phenotype of PD with early cognitive impairment and postural instability10. Multicenter prospective and large population-based studies also demonstrated that OH was a prodromal biomarker of α-synucleinopathies11–13. Therefore, OH may be used as a potential clinical marker for body-first subtype of PD. However, there are currently no clinical studies have specifically investigated this hypothesis.

OH often eludes detection in PD patients through single-shot measurements, frequently escaped from the notice of clinicians. As we all know, levodopa stands as the cornerstone and primary drug choice for PD patients14. Numerous studies have reported levodopa-induced OH in PD patients, particularly those with autonomic dysfunction15–17. Levodopa challenge test (LCT) is commonly used for evaluating responsiveness of levodopa in PD patients18, and simultaneously, blood pressure (BP) measurements can reveal OH induced by the loading dose of levodopa, shedding light on potential cardiovascular dysfunction. Hence, we aimed to investigate clinical subtypes of PD based on OH status (spontaneous, only levodopa-induced OH and non-OH), and associated clinical characteristics in a large cohort of patients with mid-later stage PD. We hypothesized that PD patients with spontaneous OH (SOH) and only levodopa-induced OH (LOH) were with similar clinical features and were both associated with the cardinal clinical features of PD patients with body-first subtypes.

Results

Demographic and clinical characteristics

The demographic and clinical characteristics were described in Table 1. The mean age of the subjects was 62.4 (±8.9) years old with a mean disease duration of 7.9 (±5.4) years. More than half of the subjects were with H&Y stage ≤2.5 (57.2%), motor fluctuations (57.4%), and FOG (47.7%). Almost one-quarter of patients (24.9%) had dyskinesias. The mean score of MDS-UPDRS-III was 54.2. More than half of the patients were classified as PIGD, and 30% patients fulfilled the criteria for the TD subtype based on motor symptoms.Table 1 Demographic and clinical characteristics based on OH subtypes

	Total (n = 928)	SOH (n = 224)	LOH (n = 321)	NOH (n = 383)	P	
Female (%)	413 (44.5)	99 (44.2)	148 (46.1)	166 (43.3)	0.759	
Age, years (mean ± SD)	62.4 ± 8.9	64.1 ± 7.7a	63.7 ± 8 .2a	60.2 ± 9.7	<0.001	
Disease duration, years (mean ± SD)	7.9 ± 5.4	8.3 ± 5.2a	8.8 ± 5.5a	7.0 ± 5.3	<0.001	
LED, mg (mean ± SD)	258.9 ± 80.0	267.2 ± 84.9a	269.1 ± 75.4a	245.8 ± 79.2	<0.001	
Asymmetric onset (%)	480 (51.7)	117 (52.2)	164 (51.1)	199 (52.0)	0.588	
Motor subtypes	
 TD (%)	279 (30.1)	64 (28.6)	91 (28.3)	124 (32.4)	0.171	
 Indeterminate (%)	83 (8.9)	14 (6.3)	35 (10.9)	34 (8.9)		
 PIGD (%)	507 (54.6)	134 (59.8)	179 (55.8)	194 (50.7)		
H&Y	
 1–2.5 (%)	531 (57.2)	120 (53.6)	170 (53.0)	241 (62.9)	0.045	
 3 (%)	257 (27.7)	69 (30.8)a	93 (29.0)	95 (24.8)		
 4–5 (%)	139 (15.0)	34 (15.2)	58 (18.1)	47 (12.3)		
 Motor fluctuations (%)	533 (57.4)	135 (60.3)	207 (64.5)a	191 (49.9)	0.002	
 Dyskinesias (%)	231 (24.9)	59 (26.3)	96 (29.9)a	76 (19.8)	0.029	
 FOG (%)	443 (47.7)	120 (53.6)	170 (53.0)a	153 (39.9)	0.001	
 MDS-UPDRS-II (mean ± SD)	18.7 ± 8.7	20.3 ± 8.7a	20.0 ± 8.5a	16.7 ± 8.5	<0.001	
 MDS-UPDRS-III (mean ± SD)	54.2 ± 19.0	57.1 ± 18.6a	57.1 ± 17.7a	50.1 ± 19.6	<0.001	
 Cognitive impairment-MMSE (%)	383 (42.3)	102 (45.5)	139 (43.3)	142 (37.1)	0.165	
 Cognitive impairment-MoCA (%)	652 (70.3)	170 (75.9)	237 (73.8)	245 (64.0)	0.022	
 PDSS (mean ± SD)	108.7 ± 25.6	106.5 ± 25.2	107.9 ± 24.2	110.6 ± 26.9	0.159	
 EDS (%)	163 (17.6)	51 (22.8)	50 (15.6)	62 (16.2)	0.097	
 pRBD (%)	466 (50.2)	151 (67.4)a, b	176 (54.8)a	139 (36.3)	<0.001	
 NMSS- cardiovascular (mean ± SD)	1.0 ± 2.2	1.3 ± 3.0a	1.0 ± 1.9	0.7 ± 1.8	0.008	
 NMSS- digestive (mean ± SD)	6.1 ± 5.8	7.3 ± 6.2a	6.9 ± 5.9a	4.7 ± 5.2	<0.001	
 Constipation (%)	614 (66.2)	171 (76.3)a	237 (73.8)a	206 (53.8)	<0.001	
 Hyposmia (%)	380 (40.9)	96 (42.9)	127 (39.6)	157 (41.0)	0.685	
 Anxiety (%)	536 (57.8)	140 (62.5)	183 (57.0)	213 (55.6)	0.315	
 Depression (%)	553 (59.6)	149 (66.5)	192 (59.8)	212 (55.4)	0.056	
 Hallucination (%)	109 (11.7)	36 (16.1)a	41 (12.8)	32 (8.4)	0.022	
 SH (%)	217 (23.4)	44 (19.6)b	98 (30.5)	75 (19.6)	0.001	
Values are mean ± SD or number (percentage).

Bold words: significant values.

OH orthostatic hypotension, SOH spontaneous OH, LOH levodopa-induced OH, NOH non-OH, LED Levodopa equivalent dose in the Levodopa Challenge Test, TD tremor dominate, PIGD postural instability/gait disorder, FOG freezing of gait, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, MMSE Mini-mental State Examination, MoCA Montreal cognitive assessment, PDSS Parkinson disease sleep scale, EDS excessive daytime sleepiness, pRBD probable rapid eye movement sleep behavior disorder, NMSS non-motor symptoms scale, SH supine hypertension.

aP < 0.05, vs NOH.

bP < 0.05, vs LOH.

Classification of PD subjects based on OH status

PD subjects were divided into three groups according to OH status. There were 545 patients (58.7%) had OH, among whom, 224 (24.1%) were found with SOH, 321 (34.6%) with LOH, and 383 (41.3%) with NOH. Most of the SOH patients (179, 80.0%) remained OH status during LCT (Fig. 1), and there were no significant differences in clinical characteristics between LOH and non-LOH subgroups among these SOH patients except the formers were with higher dose of LED, more dyskinesias, anxiety, and depression (Supplementary Table 1). Whereas only dyskinesias (OR 2.70, 1.01–7.21) remained an independent risk factor for LOH in the multivariate logistic regression model (Supplementary Table 2).Fig. 1 Definition and classification of clinical subtypes based on OH status.

PD Parkinson’s disease, OH orthostatic hypotension.

Motor and non-motor symptoms between OH subtypes

In general, both SOH and LOH patients had older age, longer disease duration, higher LED usage, and MDS-UPDRS III scores compared with NOH patients (Table 1). Patients with motor fluctuations, dyskinesias, and FOG were found more likely to develop OH, particularly for LOH. However, the distribution of different subtypes of PD based on motor symptoms (e.g., TD and PIGD) was not different among the three groups.

As to non-motor symptoms, we found that PD patients with OH, especially those with SOH were more likely to develop pRBD, hallucination, cognitive impairment, constipation, and severe cardiovascular and digestive dysfunction as compared to those without (Table 1). Importantly, only patients with LOH were more susceptible to SH (Table 1). Multivariate logistic regression analyses finally proved that compared to NOH subgroup, both SOH and LOH groups were independently associated with a higher risk of older age (SOH OR 1.03, 1.00-1.06 and LOH OR 1.03, 1.00-1.05), motor fluctuations (OR 1.80, 1.07-3.04 and OR 2.07, 1.31-3.29) and pRBD (OR 2.96, 1.87-4.69 and OR 1.76, 1.19-2.61). In addition, SOH and LOH subgroup were also more likely to be affected by cardiovascular dysfunction (OR 1.12, 1.02-1.24) and digestive dysfunction (OR 1.07, 1.03-1.11), respectively (Table 2).Table 2 Clinical features associated with different clinical subtypes based on OH status

	Univariate analysis, unadjusted OR (95%CI)		Multivariate analysis, adjusted OR (95%CI)		
SOH vs NOH	LOH vs NOH	SOH vs LOH	P	SOH vs NOH	LOH vs NOH	SOH vs LOH	P	
Female	1.04 (0.74-1.44)	1.11 (0.83-1.51)	0.93 (0.66-1.31)	0.759	-	-	-	-	
Age	1.05 (1.03-1.07)	1.05 (1.03-1.06)	1.01 (0.99-1.03)	<0.001	1.03 (1.00-1.06)	1.03 (1.00-1.05)	1.00 (0.98-1.03)	0.021	
Disease duration	1.05 (1.02-1.09)	1.07 (1.03-1.10)	0.98 (0.96-1.02)	<0.001	-	-	-	0.507	
LED	1.003 (1.001-1.006)	1.004 (1.002-1.006)	1.00 (0.99-1.00)	<0.001	-	-	-	0.714	
Asymmetric onset	0.83 (0.49-1.41)	0.79 (0.49-1.26)	1.06 (0.62-1.79)	0.586	-	-	-	-	
Motor subtypes (Ref: TD)			0.162					
PIGD	1.34 (0.92-1.94)	1.26 (0.90-1.76)	1.06 (0.72-1.57)		-	-	-	-	
Indeterminate	0.80 (0.40-1.59)	1.40 (0.81-2.42)	0.57 (0.28-1.14)		-	-	-	-	
H&Y (Ref: 1-2.5)			0.045				0.243	
3	1.46 (1.00-2.13)	1.39 (0.98-1.96)	1.05 (0.71-1.55)		-	-	-	-	
4-5	1.45 (0.89-2.38)	1.75 (1.14-2.69)	0.83 (0.51-1.35)		-	-	-	-	
Motor fluctuations	1.67 (1.08-2.60)	1.95 (1.31-2.90)	0.86 (0.53-1.38)	0.002	1.80 (1.07-3.04)	2.07 (1.31-3.29)	0.86 (0.50-1.50)	0.004	
Dyskinesias	1.40 (0.93-2.12)	1.63 (1.13-2.36)	0.86 (0.57-1.29)	0.028	-	-	-	0.274	
FOG	1.69 (1.20-2.38)	1.63 (1.20-2.22)	1.03 (0.73-1.47)	0.001	-	-	-	0.413	
MDS-UPDRS-II	1.05 (1.03-1.08)	1.05 (1.03-1.07)	1.00 (0.98-1.02)	<0.001	-	-	-	0.986	
MDS-UPDRS-III	1.02 (1.01-1.03)	1.02 (1.01-1.03)	1.00 (0.99-1.01)	<0.001	-	-	-	0.390	
Cognitive impairment-MMSE	1.35 (0.96-1.90)	1.25 (0.92-1.70)	1.08 (0.76-1.53)	0.164	-	-	-	-	
Cognitive impairment-MoCA	1.59 (1.08-2.37)	1.49 (1.05-2.12)	1.07 (0.70-1.62)	0.023	-	-	-	0.854	
PDSS	0.99 (0.99-1.00)	1.00 (0.99-1.00)	1.00 (0.99-1.01)	0.158	-	-	-	-	
EDS	1.47 (0.97-2.23)	0.95 (0.63-1.43)	1.55 (1.00-2.41)	0.105	-	-	-	-	
pRBD	3.87 (2.67-5.60)	2.27 (1.66-3.12)	1.70 (1.16-2.49)	<0.001	2.96 (1.87-4.69)	1.76 (1.19-2.61)	1.68 (1.06-2.66)	<0.001	
NMSS- cardiovascular	1.13 (1.04-1.22)	1.06 (0.98-1.15)	1.06 (0.99-1.14)	0.009	1.12 (1.02-1.24)	1.02 (0.93-1.13)	1.10 (1.01-1.19)	0.027	
NMSS-digestive	1.09 (1.05-1.12)	1.08 (1.04-1.11)	1.01 (0.98-1.04)	<0.001	1.03 (0.99-1.08)	1.07 (1.03-1.11)	0.97 (0.93-1.01)	0.005	
Hyposmia	1.00 (0.69-1.45)	0.87 (0.62-1.22)	1.14 (0.78-1.68)	0.686	-	-	-	-	
Depression	1.54 (1.08-2.18)	1.14 (0.83-1.55)	1.35 (0.94-1.95)	0.054	-	-	-	-	
Anxiety	1.27 (0.90-1.79)	0.98 (0.72-1.33)	1.29 (0.90-1.84)	0.312	-	-	-	-	
Hallucination	2.02 (1.21-3.36)	1.57 (0.96-2.56)	1.29 (0.79-2.09)	0.021	-	-	-	0.583	
SH	1.00 (0.66-1.52)	1.81 (1.28-2.55)	0.56 (0.37-0.84)	0.001	0.88(0.51-1.53)	1.75 (1.11-2.74)	0.51 (0.30-0.84)	0.009	
Odds ratio (OR), lower and upper 95% confidence intervals (95% CI) are reported from multinomial logistic regression models. Multivariate logistical regression analysis was adjusted for variables with p < 0.05 at univariate analysis.

Bold words: significant values.

OH orthostatic hypotension, SOH spontaneous OH, LOH levodopa-induced OH, NOH non-OH, LED levodopa equivalent dose in the Levodopa Challenge Test, TD tremor dominate, PIGD postural instability/gait disorder, FOG freezing of gait, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, MMSE Mini-mental State Examination, MoCA Montreal cognitive assessment, PDSS Parkinson disease sleep scale, EDS excessive daytime sleepiness, pRBD probable rapid eye movement sleep behavior disorder, NMSS non-motor symptoms scale, SH supine hypertension.

OH subtypes and quality of life

As shown in Table 3, patients with SOH and LOH achieved significantly higher scores in MDS-UPDRS total, part I, part II, part III as compared to NOH. These associations remained significant after adjusting for age and disease duration. PDQ-39 total scores and sub-scores differed across these three OH groups as well. To be more specific, SOH and LOH patients generally showed worse in total scores, mobility, activities of daily living, emotion and cognition sub-scores of PDQ-39 compared with NOH. In addition, SOH patients showed worse in stigma, communication and bodily discomfort sub-scores as compared to NOH, and worse in emotion and cognition score as compared to LOH. The associations between PDQ-39 and OH subtypes remained significant, except for bodily discomfort, even after adjusting for age and disease duration.Table 3 Comparisons of motor symptoms and quality of life between the clinical subtypes based on OH status

	SOH (n = 224)	LOH (n = 321)	NOH (n = 383)	P	
MDS-UPDRS (mean ± SD)	
 Total scores	101.5 ± 27.7a	100.6 ± 26.7a	88.7 ± 31.0	<0.001#	
 Part I	14.2 ± 6.2a	13.7 ± 6.0a	11.4 ± 5.8	<0.001#	
 Part II	20.3 ± 8.7a	20.0 ± 8.5a	16.7 ± 8.5	<0.001#	
 Part III	57.1 ± 18.6a	57.1 ± 17.7a	50.1 ± 19.6	<0.001#	
 Part IV	6.7 ± 3.9	7.0 ± 4.1a	5.7 ± 4.2	0.002#	
PDQ-39 (mean ± SD)	
 Total scores	51.3 ± 20.7a	47.6 ± 20.8a	41.0 ± 22.6	<0.001#	
 Mobility	17.1 ± 9.9a	15.8 ± 9.9a	12.3 ± 10.1	<0.001#	
 Activities of daily living	9.9 ± 5.6a	9.2 ± 5.8a	7.5 ± 6.0	<0.001#	
 Emotion	7.1 ± 4.5a, b	6.1 ± 4.6a	5.0 ± 4.5	<0.001#	
 Stigma	5.4 ± 4.0a	5.1 ± 4.0	4.5 ± 4.2	0.004#	
 Social support	1.3 ± 1.5	1.2 ± 1.3	1.1 ± 1.6	0.054	
 Cognition	4.2 ± 2.7a, b	3.5 ± 2.6a	2.8 ± 2.5	<0.001#	
 Communication	2.1 ± 2.1a	1.7 ± 1.7	1.6 ± 1.9	<0.001#	
 Bodily discomfort	3.0 ± 2.4a	2.7 ± 2.2	2.5 ± 2.3	0.018	
Bold words: significant values.

OH orthostatic hypotension, SOH spontaneous OH, LOH levodopa induced OH, NOH non-OH, MDS-UPDRS Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, PDQ-39 Parkinson’s disease questionnaire 39 item version.

aP < 0.05, vs. NOH.

bP < 0.05, vs. LOH.

#P < 0.05, adjusted for age and duration (Multiple Linear Regression).

Discussion

The current study has investigated the subtypes of PD based on OH status and associated clinical features in a large cohort of PD patients. It demonstrated that PD patients can be divided into SOH, LOH, and NOH subtypes. Generally, PD patients with OH, comprising SOH and LOH, shared similar clinical characteristics, including older age, higher probability of cardiovascular and digestive dysfunctions, motor fluctuations, and pRBD, while LOH was also associated with SH. Both two kinds of OH patients experienced worse quality of life compared to NOH, particularly in mobility, activities of daily living, emotion, and cognition. While patients with SOH had more stigma and communication problems.

Our results demonstrated that 58.7% PD patients develop OH, which is strongly associated with pronounced cardiovascular and digestive dysfunctions. Patients with OH alongside gastrointestinal, genitourinary, or sudomotor abnormalities could receive a diagnosis of pure autonomic failure (PAF)19. According to longitudinal studies, a significant proportion of those with PAF eventually develop PD, DLB, or MSA11, establishing PAF as another prodromal synuclein disease state similar to iRBD. So early identification of nOH is crucial, however, detecting OH in the early stages of the disease is challenging, many individuals with OH may not exhibit postural intolerance and other symptoms, leading clinicians to overlook blood pressure monitoring, or they may find it difficult to detect delayed OH, which could represent the early form of OH, due to inadequate orthostatic measurement time. Also, OH is not easily identified through a single blood pressure measurement. In our cohort, we found that SOH occurred in 22.6% of early-stage (HY 1-2.5) and 26.1% of mid-later stages (HY 3-5) PD patients, which are similar to previous studies, whose OH occurred in 19.5% of early-stage and 32.8% of mid-later stage PD patients20. Importantly, our research highlights that the use of the LCT significantly improved the detection rate of OH. When the LOH was included, the prevalence of OH notably increased to 54.6% in early-stage and 64.1% in mid-later stage PD patients. The induction of OH by levodopa21 suggests that this medication may further disrupt postural BP regulation, thereby revealing potential cardiovascular dysfunction. We utilized LCT to induce OH, and multiple BP measurements after administering levodopa may help uncover potential OH episodes and identify those patients with potential autonomic dysfunction.

Our results also demonstrated the presence of RBD in PD was strongly associated with OH in the cohort, which were the same to previous cross-sectional studies9,10,22–24. It could be explained by studies of Kashihara et al. 25 which demonstrated almost all individuals with RBD show significant cardiac sympathetic denervation before any damage occurs to the nigrostriatal dopamine system. Our research also showed that besides RBD, OH patients have more severe postural instability, gait disturbance, and cognitive impairment, especially the SOH group. The same to our result, a longitudinal study reported the combination of OH and RBD (“OH-RBD cluster”) was associated with the malignant phenotype of PD characterized by more rapid progression of cognitive deficits and postural instability10. SOC model research has firmly established that RBD is an important clinical marker for body-first subtype of PD5,6. Besides RBD, the body-first subtype of PD experienced more non-motor symptoms (e.g. cognitive impairment, OH), rapid disease progression and worse quality of daily life in previous studies4,26. This is similar to our study, which showed that patients with OH, in addition to being associated with RBD, had higher MDS-UPDRS II and III scores, higher levels of cognitive impairment, and poorer quality of life. Therefore, our results suggested that OH, has the potential to become a noteworthy clinical marker for a body-first subtype of PD.

Previous studies about OH in PD patients failed to differentiate between populations with SOH and those with LOH20,27. Our study further proved that the presence of RBD in PD was strongly associated with both SOH (OR: 2.96, 95%CI, 1.87-4.69) and LOH (OR: 1.76, 95%CI, 1.19-2.61) in the cohort. Both SOH and LOH groups showed prominent impairment in motor symptoms and worsened quality of life, particularly in mobility, activities of daily living, emotion, and cognition impairment. Pablo-Fernandez et al. had reported that OH was associated with a more rapid disease progression and shorter survival in patients with an autopsy-confirmed diagnosis of PD28. In addition, anxiety and depression were independent risk factors for levodopa-induced OH in PD patients with SOH, further suggesting that patients with OH may have poor prognosis, in accordance with body-first subtype29. Another finding worth noting was that, compared to LOH patients, SOH ones demonstrated a significantly higher risk of RBD, but lower risk of digestive dysfunction. This implies that it is meaningful to differentiate SOH and LOH subgroup in future research about the PAF or SOC model. In the univariate analysis, cognitive impairment exhibited significant differences; however, the multiple regression analysis revealed no discernible disparity in cognitive impairment between the groups. It is potentially attributable to the population of the current study is a surgery-set cohort that cover all stages of PD patients rather than a pure early-stage PD population.

There are some limitations in our study. Our patients were mainly recruited from a prospective surgery-set cohort with comprehensive DBS therapy assessment. In the study of clinical biomarkers, the earlier stage of PD patients might be better candidates. Because the SOC model suggests the two subtypes are prone to showing more differences of clinical and imaging indicators in early-stage of PD patients and may converge because of the increasing amounts and dissemination of α-syn pathology during the progression of disease. However, our cohort that contained the whole stage of PD patients with 57.2% of 1-2.5 H-Y stage patients, might be more suitable for the real-world observative study. Further study will be focus on more early or prodromal phase PD populations to confirm our findings. Secondly, we primarily utilized questionnaires and scales to assess clinical symptoms of patients, lacking more objective examinations for confirming PD diagnosis and delineating disease progression. For instance, polysomnography diagnoses RBD, FDOPA PET and DaT SPECT evaluate motor symptom asymmetry, and MIBG assesses cardiac sympathetic function. However, more examination might lead to a reduction in the study population. Sub studies in a more precise cohort with PET or blood biomarker examination will be our future work. The current study is imperative for subsequent studies to validate these findings and future longitudinal study with a longer follow-up is also warranted.

In conclusion, this cross-sectional study with a large cohort of advanced-stage PD patients revealed that over half of PD patients could develop OH which is associated with pRBD, autonomic dysfunction, disease severity, cognitive and psychological symptoms, and worse quality of daily life. These clinical characteristics are consistent with the body-first subtype of PD. OH may be a noteworthy clinical marker of the body-first subtype of PD, and LCT may be a potential test to uncover this phenotype.

Methods

Study population

1353 patients who underwent LCT at the Parkinson and Movement Disorder Center of Xuanwu Hospital Capital Medical University and Beijing Ruian Rehabilitation Hospital from June 2017 to January 2020 were included, and the majority of the subjects were under the pre-operative evaluation. 928 patients fulfilled the diagnosis of “clinically probable PD” or “clinically established PD” according to Movement Disorders Society (MDS) Clinical Diagnostic Criteria for PD30 and had complete BP measurements were enrolled. All participants provided written informed consent which has been approved by the Research Ethics Committee of Xuanwu Hospital Capital Medical University.

LCT

Each patient took a regular morning levodopa equivalent dose (LED) plus 50% for the LCT after 12 hours drug-free overnight. LED was calculated using the method of Claire L et al. 31. Movement Disorders Society version of Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS-III)32 and supine-to-standing test (STS) was performed according to guideline33 before and after levodopa administration at 30-min, 1-hour, 2-hour, 3-hour and 4-hour. BP was measured repeatedly in supine position and standing position for 3 min (Omron HEM-7124; Kyoto, Japan) in each STS.

OH assessment

OH was defined as a BP decrease no less than 20 mmHg in systolic blood pressure (SBP) and/or no less than 10 mmHg in diastolic blood pressure (DBP) for subjects without supine hypertension (SH)34, and no less than 30 mmHg in SBP and/or no less than 15 mmHg in DBP for subjects with SH after 3 mins of standing35. SH was defined as SBP ≥ 150 mmHg or DBP ≥ 90 mmHg in the supine position36.

PD patients were categorized into groups: spontaneous OH (SOH), only levodopa-induced OH (LOH) and non-OH (NOH). SOH was defined as OH occurred at baseline evaluation before levodopa intake; LOH was defined as OH occurred at any time points after taking levodopa among patients without SOH. NOH was defined as OH not occurred at any timepoints both before and after taking levodopa.

Clinical assessment

All patients received standardized assessments conducted by qualified examiners before the test. Demographic information including age, gender, and disease duration were collected. To assess the asymmetry of disease onset, we queried the history of unilateral versus bilateral symptom onset37. The non-motor symptoms of the cardiovascular system and digestive system were evaluated by item 1 and 6 of the Non-Motor Symptom Scale (NMSS), respectively38. Non-motor symptoms in daily living were assessed by MDS-UPDRS Part I (MDS-UPDRS-I). MDS-UPDRS Part II (MDS-UPDRS-II) was used to assess the impact of motor symptoms on activities of daily living, which was also evaluated with the 39-item Parkinson’s Disease Questionnaire (PDQ-39)39.

Anxiety40, depression41, probable RBD (pRBD)42, and excessive daytime sleepiness (EDS)43 were defined as the total scores of Hamilton Anxiety Rating Scale (HAMA) ≥ 740, Hamilton Depression Rating Scale (HAMD-17) ≥ 841, The Hong-Kong version of REM sleep behavior disorder questionnaire (RBDQ-HK) > 1842 and Epworth Sleepiness Scale (ESS) > 643, respectively. Sleep quality was assessed by the Parkinson disease sleep scale (PDSS)44. Cognitive impairment was defined as total scores of Mini-mental State Examination (MMSE) ≤ 26 and Montreal cognitive assessment (MoCA)<2645. Constipation was defined if NMSS-21 > 0. Hallucination was defined as MDS-UPDRS-II item 2 ≥ 1. Hyposmia was defined as 6-item Hyposmia Rating Scale <22.546.

Clinical subtypes

Patients were classified as exhibiting freezing of gait (FOG) based on a score ≥ 1 on the MDS-UPDRS-II item 13. Motor fluctuations and dyskinesias were defined as MDS-UPDRS-IV item 3 ≥ 1 and item 1 ≥ 1, separately. The revised Hoehn & Yahr (H&Y) scale was used for disease staging47. Based on H&Y, PD patients were divided into the following three subgroups: early-stage (H&Y ≤ 2.5), middle-stage (H&Y = 3) and advanced stage (H&Y > 3). The ratio of the mean tremor scores (MDS-UPDRS-II item 10 and MDS-UPDRS-III items 15 -18 divided by 11) to the mean postural instability and gait difficulty (PIGD) scores (MDS-UPDRS-II items 12 -13 and MDS-UPDRS-III items 10 -12 divided by 5) was used to define tremor dominant (TD) (ratio ≥ 1.15), PIGD (ratio ≤ 0.9), and indeterminate (ratios > 0.9 and < 1.15) subtypes of patients with PD48.

Statistical analysis

Data were first tested for normality. Then different subgroups were compared for clinical features with parametric (analysis of variance, student’s t-test, chi-square test, and Fisher’s exact test) or non-parametric statistical tests (Kruskal-Wallis and Mann-Whitney test) as appropriate. For multiple comparisons, Bonferroni’s correction was applied.

To explore the clinical features of subtype groups, multinomial logistic analyses were performed. Clinical features with P < 0.05 in univariate analysis were chosen to be entered into the multivariate regression model. Backward stepwise logistic regression was performed, with P-to-remove set at 0.10. Correlations between the LOH in patients with SOH and clinical features were evaluated by binary logistic regression analysis.

To assess the differences in the dependent variables (PDQ-39 and MDS-UPDRSI-IV) while adjusting for age and disease duration, multiple linear regression was employed. The independent variables were the OH groups: SOH, LOH, and NOH.

All statistical analyses were performed using IBM SPSS Statistics for Windows (version 26.0, IBM Corp). Two-tailed P values < 0.05 were considered significant.

Supplementary information

Supplementary Tables

Supplementary information

The online version contains supplementary material available at 10.1038/s41531-024-00787-y.

Acknowledgements

The authors thank all the nurses and patients for their dedication and contributions to this study. This study was supported by grants from the National Key R&D Program of China (No. 2021YFC2501200, No.2018YFC1312001, No. 2020YFC2007304), National Natural Science Foundation of China (No. 82201401) and Xuanwu Youth Development Project (No. QNPY2021011).

Author contributions

S.M. and X.W. served as the primary contributors to the writing process, while X.W. and Y.L. were responsible for data collection and collation. C.H. conducted the statistical analysis. Z.T., W.M., C.H. and P.C. participated in the thorough review and verification of the manuscript. All authors read and approved the final manuscript.

Data availability

Anonymized data generated during the current study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Shanshan Mei, Xue Wang.
==== Refs
References

1. Sauerbier A Jenner P Todorova A Chaudhuri KR Non motor subtypes and Parkinson’s disease Parkinson. Relat. Disord. 2016 22 S41 S46 10.1016/j.parkreldis.2015.09.027
Sauerbier, A., Jenner, P., Todorova, A. & Chaudhuri, K. R. Non motor subtypes and Parkinson’s disease. Parkinson. Relat. Disord. 22, S41–S46 (2016).10.1016/j.parkreldis.2015.09.027
2. Marras C Chaudhuri KR Nonmotor features of Parkinson’s disease subtypes Mov. Disord.: Off. J. Mov. Disord. Soc. 2016 31 1095 1102 10.1002/mds.26510
Marras, C. & Chaudhuri, K. R. Nonmotor features of Parkinson’s disease subtypes. Mov. Disord.: Off. J. Mov. Disord. Soc. 31, 1095–1102 (2016).10.1002/mds.26510
3. Borghammer P Van Den Berge N Brain-First versus Gut-First Parkinson’s disease: a hypothesis J. Parkinson’s Dis. 2019 9 S281 S295 10.3233/JPD-191721 31498132
Borghammer, P. & Van Den Berge, N. Brain-First versus Gut-First Parkinson’s disease: a hypothesis. J. Parkinson’s Dis. 9, S281–S295 (2019).31498132 10.3233/JPD-191721
4. Borghammer P The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s disease: Explaining motor asymmetry, non-motor phenotypes, and cognitive decline J. Parkinson’s Dis. 2021 11 455 474 10.3233/JPD-202481 33682732
Borghammer, P. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s disease: Explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J. Parkinson’s Dis. 11, 455–474 (2021).33682732 10.3233/JPD-202481
5. Horsager J Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study Brain: J. Neurol. 2020 143 3077 3088 10.1093/brain/awaa238
Horsager, J. et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain: J. Neurol. 143, 3077–3088 (2020).10.1093/brain/awaa238
6. Knudsen K Asymmetric Dopaminergic dysfunction in brain-first versus body-first Parkinson’s disease subtypes J. Parkinson’s Dis. 2021 11 1677 1687 10.3233/JPD-212761 34334424
Knudsen, K. et al. Asymmetric Dopaminergic dysfunction in brain-first versus body-first Parkinson’s disease subtypes. J. Parkinson’s Dis. 11, 1677–1687 (2021).34334424 10.3233/JPD-212761
7. Kim JS Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder J. Neurol. Sci. 2016 362 59 63 10.1016/j.jns.2016.01.020 26944118
Kim, J. S. et al. Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with REM sleep behavioral disorder. J. Neurol. Sci. 362, 59–63 (2016).26944118 10.1016/j.jns.2016.01.020
8. Pilotto A Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies J. Neurol. Neurosurg. Psychiatry 2019 90 1257 1263 10.1136/jnnp-2019-320846 31142660
Pilotto, A. et al. Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies. J. Neurol. Neurosurg. Psychiatry 90, 1257–1263 (2019).31142660 10.1136/jnnp-2019-320846
9. Yin K REM sleep behavioral disorder may be an independent risk factor for orthostatic hypotension in Parkinson’s disease Aging Clin. Exp. Res. 2022 34 159 166 10.1007/s40520-021-01887-y 34021898
Yin, K. et al. REM sleep behavioral disorder may be an independent risk factor for orthostatic hypotension in Parkinson’s disease. Aging Clin. Exp. Res. 34, 159–166 (2022).34021898 10.1007/s40520-021-01887-y
10. Fereshtehnejad SM New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes JAMA Neurol. 2015 72 863 873 10.1001/jamaneurol.2015.0703 26076039
Fereshtehnejad, S. M. et al. New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 72, 863–873 (2015).26076039 10.1001/jamaneurol.2015.0703
11. Kaufmann H Natural history of pure autonomic failure: A United States prospective cohort Ann. Neurol. 2017 81 287 297 10.1002/ana.24877 28093795
Kaufmann, H. et al. Natural history of pure autonomic failure: A United States prospective cohort. Ann. Neurol. 81, 287–297 (2017).28093795 10.1002/ana.24877
12. Postuma RB Gagnon JF Pelletier A Montplaisir J Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies Mov. Disord. 2013 28 597 604 10.1002/mds.25445 23554107
Postuma, R. B., Gagnon, J. F., Pelletier, A. & Montplaisir, J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Mov. Disord. 28, 597–604 (2013).23554107 10.1002/mds.25445
13. Schrag A Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study Lancet Neurol. 2015 14 57 64 10.1016/S1474-4422(14)70287-X 25435387
Schrag, A. et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 14, 57–64 (2015).25435387 10.1016/S1474-4422(14)70287-X
14. Pursiainen V Blood pressure and heart rate in Parkinsonian patients with and without wearing-off Eur. J. Neurol. 2007 14 373 378 10.1111/j.1468-1331.2007.01672.x 17388983
Pursiainen, V. et al. Blood pressure and heart rate in Parkinsonian patients with and without wearing-off. Eur. J. Neurol. 14, 373–378 (2007).17388983 10.1111/j.1468-1331.2007.01672.x
15. Fabbri M Response of non-motor symptoms to levodopa in late-stage Parkinson’s disease: Results of a levodopa challenge test Parkinson. Relat. Disord. 2017 39 37 43 10.1016/j.parkreldis.2017.02.007
Fabbri, M. et al. Response of non-motor symptoms to levodopa in late-stage Parkinson’s disease: Results of a levodopa challenge test. Parkinson. Relat. Disord. 39, 37–43 (2017).10.1016/j.parkreldis.2017.02.007
16. Li K Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease Sci. Rep. 2017 7 7012 10.1038/s41598-017-07429-9 28765629
Li, K. et al. Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease. Sci. Rep. 7, 7012 (2017).28765629 10.1038/s41598-017-07429-9
17. Haapaniemi TH Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease J. Neurol. 2000 247 868 874 10.1007/s004150070075 11151420
Haapaniemi, T. H. et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease. J. Neurol. 247, 868–874 (2000).11151420 10.1007/s004150070075
18. Saranza G Lang AE Levodopa challenge test: indications, protocol, and guide J. Neurol. 2021 268 3135 3143 10.1007/s00415-020-09810-7 32333167
Saranza, G. & Lang, A. E. Levodopa challenge test: indications, protocol, and guide. J. Neurol. 268, 3135–3143 (2021).32333167 10.1007/s00415-020-09810-7
19. Coon EA Singer W Low PA Pure autonomic failure Mayo Clin. Proc. 2019 94 2087 2098 10.1016/j.mayocp.2019.03.009 31515103
Coon, E. A., Singer, W. & Low, P. A. Pure autonomic failure. Mayo Clin. Proc. 94, 2087–2098 (2019).31515103 10.1016/j.mayocp.2019.03.009
20. Hiorth YH Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study Neurology 2019 93 e1526 e1534 10.1212/WNL.0000000000008314 31527282
Hiorth, Y. H. et al. Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study. Neurology 93, e1526–e1534 (2019).31527282 10.1212/WNL.0000000000008314
21. Liu Z Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson’s disease: Results of acute levodopa challenge test Parkinson. Relat. Disord. 2023 115 105860 10.1016/j.parkreldis.2023.105860
Liu, Z. et al. Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson’s disease: Results of acute levodopa challenge test. Parkinson. Relat. Disord. 115, 105860 (2023).10.1016/j.parkreldis.2023.105860
22. Arnaldi D De Carli F Prediction of cognitive worsening in de novo Parkinson’s disease: Clinical use of biomarkers Mov. Disord. 2017 32 1738 1747 10.1002/mds.27190 29119593
Arnaldi, D. & De Carli, F. Prediction of cognitive worsening in de novo Parkinson’s disease: Clinical use of biomarkers. Mov. Disord. 32, 1738–1747 (2017).29119593 10.1002/mds.27190
23. Sommerauer M Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study Brain: J. Neurol. 2018 141 496 504 10.1093/brain/awx348
Sommerauer, M. et al. Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain: J. Neurol. 141, 496–504 (2018).10.1093/brain/awx348
24. Postuma RB Cardiac autonomic denervation in Parkinson’s disease is linked to REM sleep behavior disorder Mov. Disord. 2011 26 1529 1533 10.1002/mds.23677 21538520
Postuma, R. B. et al. Cardiac autonomic denervation in Parkinson’s disease is linked to REM sleep behavior disorder. Mov. Disord. 26, 1529–1533 (2011).21538520 10.1002/mds.23677
25. Kashihara K Imamura T Shinya T Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson’s disease Parkinson. Relat. Disord. 2010 16 252 255 10.1016/j.parkreldis.2009.12.010
Kashihara, K., Imamura, T. & Shinya, T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson’s disease. Parkinson. Relat. Disord. 16, 252–255 (2010).10.1016/j.parkreldis.2009.12.010
26. Pavelka L Body-first subtype of parkinson’s disease with probable REM-sleep behavior disorder is associated with non-motor dominant phenotype J. Parkinson’s Dis. 2022 12 2561 2573 10.3233/JPD-223511 36245388
Pavelka, L. et al. Body-first subtype of parkinson’s disease with probable REM-sleep behavior disorder is associated with non-motor dominant phenotype. J. Parkinson’s Dis. 12, 2561–2573 (2022).36245388 10.3233/JPD-223511
27. Palma JA Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov. Disord. 2015 30 639 645 10.1002/mds.26079 25678194
Palma, J. A. et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?. Mov. Disord. 30, 639–645 (2015).25678194 10.1002/mds.26079
28. De Pablo-Fernandez E Association of autonomic dysfunction with disease progression and survival in Parkinson disease JAMA Neurol. 2017 74 970 976 10.1001/jamaneurol.2017.1125 28655059
De Pablo-Fernandez, E. et al. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol. 74, 970–976 (2017).28655059 10.1001/jamaneurol.2017.1125
29. Pagano G REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease Neurology 2018 91 e894 e905 10.1212/WNL.0000000000006134 30089615
Pagano, G. et al. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology 91, e894–e905 (2018).30089615 10.1212/WNL.0000000000006134
30. Postuma RB MDS clinical diagnostic criteria for Parkinson’s disease Mov. Disord. 2015 30 1591 1601 10.1002/mds.26424 26474316
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).26474316 10.1002/mds.26424
31. Tomlinson CL Systematic review of levodopa dose equivalency reporting in Parkinson’s disease Mov. Disord. 2010 25 2649 2653 10.1002/mds.23429 21069833
Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25, 2649–2653 (2010).21069833 10.1002/mds.23429
32. Goetz CG Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results Mov. Disord. 2008 23 2129 2170 10.1002/mds.22340 19025984
Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).19025984 10.1002/mds.22340
33. Juraschek SP Association of history of dizziness and long-term adverse outcomes with early vs later orthostatic hypotension assessment times in middle-aged adults JAMA Intern. Med. 2017 177 1316 1323 10.1001/jamainternmed.2017.2937 28738139
Juraschek, S. P. et al. Association of history of dizziness and long-term adverse outcomes with early vs later orthostatic hypotension assessment times in middle-aged adults. JAMA Intern. Med. 177, 1316–1323 (2017).28738139 10.1001/jamainternmed.2017.2937
34. Lahrmann H EFNS guidelines on the diagnosis and management of orthostatic hypotension Eur. J. Neurol. 2006 13 930 936 10.1111/j.1468-1331.2006.01512.x 16930356
Lahrmann, H. et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur. J. Neurol. 13, 930–936 (2006).16930356 10.1111/j.1468-1331.2006.01512.x
35. Freeman R Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome Clin. Auton. Res. 2011 21 69 72 10.1007/s10286-011-0119-5 21431947
Freeman, R. et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 21, 69–72 (2011).21431947 10.1007/s10286-011-0119-5
36. Gibbons CH The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension J. Neurol. 2017 264 1567 1582 10.1007/s00415-016-8375-x 28050656
Gibbons, C. H. et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J. Neurol. 264, 1567–1582 (2017).28050656 10.1007/s00415-016-8375-x
37. Postuma RB Gagnon JF Symmetry of Parkinson’s disease and REM sleep: one piece of the puzzle Ann. Neurol. 2011 69 905 10.1002/ana.22259 21254194
Postuma, R. B. & Gagnon, J. F. Symmetry of Parkinson’s disease and REM sleep: one piece of the puzzle. Ann. Neurol. 69, 905 (2011).21254194 10.1002/ana.22259
38. Martinez-Martin P International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease Neurology 2009 73 1584 1591 10.1212/WNL.0b013e3181c0d416 19901251
Martinez-Martin, P. et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 73, 1584–1591 (2009).19901251 10.1212/WNL.0b013e3181c0d416
39. Jenkinson C The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score Age Ageing 1997 26 353 357 10.1093/ageing/26.5.353 9351479
Jenkinson, C. et al. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26, 353–357 (1997).9351479 10.1093/ageing/26.5.353
40. Matza LS Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder Int. J. Methods Psychiatr. Res. 2010 19 223 232 10.1002/mpr.323 20718076
Matza, L. S. et al. Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int. J. Methods Psychiatr. Res. 19, 223–232 (2010).20718076 10.1002/mpr.323
41. Zimmerman M Severity classification on the Hamilton Depression Rating Scale J. Affect. Disord. 2013 150 384 388 10.1016/j.jad.2013.04.028 23759278
Zimmerman, M. et al. Severity classification on the Hamilton Depression Rating Scale. J. Affect. Disord. 150, 384–388 (2013).23759278 10.1016/j.jad.2013.04.028
42. Shen SS Validation study of REM sleep behavior disorder questionnaire-Hong Kong (RBDQ-HK) in east China Sleep. Med. 2014 15 952 958 10.1016/j.sleep.2014.03.020 24938584
Shen, S. S. et al. Validation study of REM sleep behavior disorder questionnaire-Hong Kong (RBDQ-HK) in east China. Sleep. Med. 15, 952–958 (2014).24938584 10.1016/j.sleep.2014.03.020
43. Marinus J Assessment of sleep and sleepiness in Parkinson disease Sleep 2003 26 1049 1054 10.1093/sleep/26.8.1049 14746389
Marinus, J. et al. Assessment of sleep and sleepiness in Parkinson disease. Sleep 26, 1049–1054 (2003).14746389 10.1093/sleep/26.8.1049
44. Chaudhuri KR The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease J. Neurol., Neurosurg., psychiatry 2002 73 629 635 10.1136/jnnp.73.6.629 12438461
Chaudhuri, K. R. et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J. Neurol., Neurosurg., psychiatry 73, 629–635 (2002).12438461 10.1136/jnnp.73.6.629
45. Chun CT Seward K Patterson A Evaluation of available cognitive tools used to measure mild cognitive decline: a scoping review Nutrients. 2021 13 3974 10.3390/nu13113974 34836228
Chun, C. T., Seward, K. & Patterson, A. Evaluation of available cognitive tools used to measure mild cognitive decline: a scoping review. Nutrients. 13, 3974 (2021).34836228 10.3390/nu13113974
46. Millar Vernetti P Validation of a new scale to assess olfactory dysfunction in patients with Parkinson’s disease Parkinson. Relat. Disord. 2012 18 358 361 10.1016/j.parkreldis.2011.12.001
Millar Vernetti, P. et al. Validation of a new scale to assess olfactory dysfunction in patients with Parkinson’s disease. Parkinson. Relat. Disord. 18, 358–361 (2012).10.1016/j.parkreldis.2011.12.001
47. Goetz CG Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations Mov. Disord. 2004 19 1020 1028 10.1002/mds.20213 15372591
Goetz, C. G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 19, 1020–1028 (2004).15372591 10.1002/mds.20213
48. Stebbins GT How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale Mov. Disord. 2013 28 668 670 10.1002/mds.25383 23408503
Stebbins, G. T. et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. Mov. Disord. 28, 668–670 (2013).23408503 10.1002/mds.25383
